Medscape Conference Coverage, based on selected sessions at the:
34th Annual Meeting of the American Society of Clinical Oncology
May 16 - 19, 1998, Los Angeles, California
This activity is not sanctioned by, nor a part of, the 34th Annual Meeting of the American Society of Clinical Oncology.
Topic Overviews
34th Annual Meeting of the American Society of Clinical Oncology Anti-HER-2 Antibody -- Effective as Single Agent and in Combination with Standard Therapy Stuart S. Lichtman, MD Special Introduction to Integrated Session on HER-2/neu Harold J. Burstein, MD PhD Antitumor Peptide Vaccine Induces Specific T-Cell Immunity to HER-2/neu Philip Schulman, MD More...
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape, Inc., and do not represent a publication of the American Society of Clinical Oncology. These materials and the related activity are not sanctioned by the American Society of Clinical Oncology or the sponsors of the conference, and do not constitute an official part of that conference.
The material presented here does not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing medical education activity.
Anti-HER-2 Antibody -- Effective as Single Agent and in Combination with Standard Therapy